Cannabis and Cannabinoid Research (http://www.liebertpub.com/can), the peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/), announces a new collaborative partnership with the International Association for Cannabinoid Medicines. This new collaboration promotes the missions of the Journal and Association to further the science of clinical cannabis, cannabinoids, and the endocannabinoid system, for potential therapeutic and medical application.
For the past 16 years, the International Association for Cannabinoid Medicines (IACM) (http://www.cannabis-med.org/) has been dedicated to advancing the knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics with regard to their therapeutic potential. The IACM organizes a highly regarded biennial Conference on Cannabinoids in Medicine. "The IACM welcomes this collaboration with Cannabis and Cannabinoid Research," says Dr. Mark A. Ware, Chairman of IACM. "We are particularly excited about increasing the amount of published clinical research that will become available for healthcare professionals and decision makers."
Led by Editor-in-Chief Daniele Piomelli, PhD, PharmD, Cannabis and Cannabinoid Research (http://www.liebertpub.com/can) provides an important open access venue for publishing the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system. The Journal publishes a broad range of human and animal studies, including basic and translational research; clinical studies; and behavioral, social, and epidemiological issues.
"We are happy to have the International Association for Cannabinoid Medicines as a partner. They have a strong commitment to furthering the knowledge of cannabis and cannabinoid medicines", says Jordan L. Schilling, Director of Open Access Publishing at Mary Ann Liebert, Inc., publishers. "The partnership will be an excellent fit for both the IACM and Cannabis and Cannabinoid Research (http://www.liebertpub.com/can)."